<SEC-DOCUMENT>0001437749-20-023720.txt : 20201113
<SEC-HEADER>0001437749-20-023720.hdr.sgml : 20201113
<ACCEPTANCE-DATETIME>20201113072919
ACCESSION NUMBER:		0001437749-20-023720
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20201113
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201113
DATE AS OF CHANGE:		20201113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moleculin Biotech, Inc.
		CENTRAL INDEX KEY:			0001659617
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474671999
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37758
		FILM NUMBER:		201309167

	BUSINESS ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
		BUSINESS PHONE:		713-300-5160

	MAIL ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mbrx20201110_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:mbrx="http://www.mbrx.com/20201113" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31"><head>
	<title>mbrx20201110_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 11/10/2020 2:26:09 PM -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20208K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20208K" name="dei:EntityCentralIndexKey">0001659617</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="mbrx-20201113.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20208K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-11-13</xbrli:startDate>
<xbrli:endDate>2020-11-13</xbrli:endDate>
</xbrli:period>
</xbrli:context>


</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>UNITED STATES</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>WASHINGTON, D.C. 20549</b></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>FORM <ix:nonNumeric contextRef="d20208K" name="dei:DocumentType"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CURRENT REPORT</b></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): </b><ix:nonNumeric contextRef="d20208K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><b>November 13</b><b>, 2020</b></ix:nonNumeric></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</div>

<div style="text-align: center;"><img alt="logo.jpg" src="logo.jpg" /></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20208K" name="dei:EntityRegistrantName"><b>MOLECULIN BIOTECH, INC.</b></ix:nonNumeric></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Exact Name of Registrant as Specified in its Charter)</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20208K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="text-transform:uppercase;">delaware</span></ix:nonNumeric></div>
			</td>
			<td style="vertical-align: middle; width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20208K" name="dei:EntityFileNumber"><b>001-37758</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align: middle; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20208K" name="dei:EntityTaxIdentificationNumber"><b>47-4671997</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(State or Other Jurisdiction of Incorporation or Organization)</div>
			</td>
			<td style="vertical-align: top; width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Commission File No.)</div>
			</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(I.R.S. Employer Identification No.)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><ix:nonNumeric contextRef="d20208K" name="dei:EntityAddressAddressLine1"><b>5300 Memorial Drive, Suite 950</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20208K" name="dei:EntityAddressCityOrTown"><b>Houston</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20208K" name="dei:EntityAddressStateOrProvince"><b>TX</b></ix:nonNumeric> <ix:nonNumeric contextRef="d20208K" name="dei:EntityAddressPostalZipCode"><b>77007</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Address of principal executive offices and zip code)</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&#xa0;</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(<ix:nonNumeric contextRef="d20208K" name="dei:CityAreaCode"><b>713</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20208K" name="dei:LocalPhoneNumber"><b>300-5160</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Registrant&#8217;s telephone number, including area code)</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Former name or former address, if changed from last report)</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General Instruction A.2. below):</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:100%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><ix:nonNumeric contextRef="d20208K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:100%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><ix:nonNumeric contextRef="d20208K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:100%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><ix:nonNumeric contextRef="d20208K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:100%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><ix:nonNumeric contextRef="d20208K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#xa0; Emerging growth company <ix:nonNumeric contextRef="d20208K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="d20208K" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod">&#9746;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align: bottom; width: 35%; border-color: black; border-style: solid; border-width: 1px;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Title of each class</b></div>
			</td>
			<td style="vertical-align: bottom; width: 30%; border-top: 1px solid black; border-bottom: 1px solid black; border-right: 1px solid black;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Trading Symbol (s)</b></div>
			</td>
			<td style="vertical-align: bottom; width: 35%; border-top: 1px solid black; border-bottom: 1px solid black; border-right: 1px solid black;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Name of each exchange on which registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 35%; border-left: 1px solid black; border-right: 1px solid black;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20208K" name="dei:Security12bTitle">Common Stock</ix:nonNumeric>, par value $.001 per share</div>
			</td>
			<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 30%; border-right: 1px solid black;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20208K" name="dei:TradingSymbol">MBRX</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 35%; border-right: 1px solid black;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20208K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The NASDAQ Stock Market LLC</ix:nonNumeric></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item 2.02&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</b><b>Results of Operations and Financial Condition.</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">On November 13, 2020, Moleculin Biotech, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the quarter ended September 30, 2020 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Item 9.01 &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;Financial Statements and Exhibits.</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>&#xa0;</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(d)&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;Exhibits.</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Exhibit No. </b></div>
			</td>
			<td>
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Description</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">99.1</div>
			</td>
			<td>
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_213101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Press Release dated </span><span style="text-decoration: underline;">November 13</span><span style="text-decoration: underline;">, 2020</span></a></div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">104</div>
			</td>
			<td>
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Cover page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline;"><b>SIGNATURE</b></span></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>MOLECULIN BIOTECH, INC.</b></td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Date: November 13, 2020</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">By: <span style="text-decoration: underline;">/s/ Jonathan P. Foster</span></td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Jonathan P. Foster</div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Chief Financial Officer</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>EXHIBIT INDEX</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="text-decoration: underline;"><b>Exhibit </b></span></div>
			</td>
			<td>
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="text-decoration: underline;"><b>No.</b></span><b> </b><span style="text-decoration: underline;"><b>Description</b></span></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">99.1</div>
			</td>
			<td>
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Press Release dated November 13, 2020</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">104</div>
			</td>
			<td>
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Cover page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_213101.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_213101.htm</title>
	<!-- Generated by ThunderDome Portal - 11/11/2020 3:28:53 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Exhibit 99.1</b></p>

<div><img alt="logo.jpg" src="logo.jpg"></div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 22pt; margin: 0pt; text-align: center;"><font style="color:#006699;"><b>Moleculin Biotech, Inc. Reports Financial Results </b></font></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 22pt; margin: 0pt; text-align: center;"><font style="color:#006699;"><b>for the Quarter Ended September 30, 2020</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 22pt; margin: 0pt; text-align: center;">&nbsp;</p>

<div style="display: none;">&nbsp;</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0px; text-align: justify;">HOUSTON, November 13, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the quarter ended September 30, 2020 and provided a business update.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:left;"><b>Management Discussion</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">"We are extremely encouraged by the progress we made in the third quarter. Despite the sustained headwinds from the COVID-19 pandemic, we were able to drive the development of Annamycin both in our AML and lung indications, further progress our clinical trials for WP1066, expand and accelerate our infectious disease platform, and bolster our experienced leadership team,&#8221; commented Walter Klemp, Chairman and CEO of Moleculin.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#8220;We were particularly encouraged by the progress we made advancing our lead candidate Annamycin, a &#8216;next generation anthracycline&#8217; demonstrating little to no cardiotoxicity. In June, we conducted our End of Phase 1 meeting with the US Food and Drug Administration ("FDA"). As a result of this meeting, we will expand our protocol-mandated testing for cardiotoxicity throughout the remainder of the Phase 1 trial. This will provide additional safety data, including investigating the continued evidence of little to no cardiotoxicity, and efficacy data which both US and European regulators may consider as we prepare to transition to a Phase 2 clinical trial. We also received approval from Polish authorities to increase the dose-escalation from 30 mg/m2 per cohort to 60 mg/m2 per cohort which will accelerate finding the maximum tolerated dose.&#8221;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#8220;We were also excited by the promise Annamycin shows in targeting lung localized tumors. Currently there is an extreme unmet need for a more effective treatment of sarcomas that have metastasized to the lungs, and limited treatment options available for lung metastases resulting from a primary tumor, even though the primary tumor may have been treatable. In September, we were pleased to announce results from an independent laboratory demonstrating in animal studies the ability of Annamycin to generate a 30-fold greater concentration in lungs compared to the current standard of care drug, enabling the targeting of this cancer in its sanctuary site. These results further validate data we presented at the American Association of Cancer Research, which illustrated Annamycin&#8217;s uniquely high uptake and retention in the lungs, resulting in consistently high in vivo activity against a wide range of lung-localized tumors in mice. Due to Annamycin&#8217;s strong pre-clinical data in this indication, we successfully completed a pre-IND (Investigational New Drug) meeting with the FDA and discussed our development plan for Annamycin, including the clinical study design and dosing strategy for an initial Phase 1b/2 protocol for soft tissue sarcomas with lung metastases. Based on our conversations, and the compelling pre-clinical data, we are optimistic that we will be able to file an IND with the FDA for this indication before the end of the year.&#8221;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#8220;In addition to driving the development of Annamycin, we continued to advance WP1066, the lead molecule in Moleculin&#8217;s portfolio of immune stimulators and modulators of transcription. Importantly, we were able to report positive data from both our adult and pediatric Phase 1 clinical trials. In our adult Phase 1 clinical trial being conducted at a major cancer center in Houston, we reported positive preliminary data in adult patients with glioblastoma (&#8220;GBM&#8221;), which supports the progression of the trial to the fourth and final dose escalation cohort. In our Phase 1 clinical trial of WP1066 for the treatment of brain tumors in children being at conducted at the Aflac Cancer &amp; Blood Disorders Center at Children&#8217;s Healthcare of Atlanta, the first three patients in the trial received treatment at a dose level of 4 mg/kg with no adverse events related to WP1066 and the study is now proceeding to the next higher dose of 6 mg/kg. Importantly, one patient with diffuse intrinsic pontine glioma (&#8220;DIPG&#8221;), showed an apparent response to the treatment with both clinical improvement and radiologic reduction of tumor size. We believe this to be particularly notable given the clinical trial history of DIPG, as approximately 200 clinical trials have been conducted with no drug showing significant activity in this disease.&#8221;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#8220;Although we remain laser focused on advancing our clinical pipeline, we are very encouraged by the potential our infectious disease pipeline continues to offer. Our initial preclinical focus for the WP1122 program was to help provide a treatment for the growing COVID-19 pandemic. Following strong preclinical data and independent research demonstrating WP1122&#8217;s unique mechanism of action and in-vitro activity, we were pleased to further progress our studies as we prepare for submission of an IND to test WP1122 in COVID-19 patients. During the quarter, we also discovered that two other molecules within our portfolio of antimetabolites displayed significant in vitro antiviral activity against SARS-CoV-2 and other hard to treat viruses. Independent laboratory testing of our new drug candidates, called WP1096 and WP1097, not only showed significant antiviral activity against SARS-CoV-2, but also showed greater potential against HIV, Zika, and Dengue Fever. While we are encouraged by the strong preclinical data, we believe our best course of action for advancing this portfolio given its early stage will be through relying on collaborations and externally funded pathways. Subsequently, we entered into an agreement with the University of Campinas in S&#227;o Paulo, Brazil to further enable collaboration into research on the anti-viral capabilities of WP1122, specifically for the coronavirus. We continue to be optimistic about the data demonstrated in the WP1122 portfolio and are planning to file an IND application or its equivalent for either cancer-related or virus-related clinical trials in the first half of 2021.&#8221;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Mr. Klemp concluded, &#8220;As we head into the final months of 2020, we believe we remain well-positioned to progress our three core technologies. To help drive this effort, we recently appointed Liz Cermak to our Board of Directors. Liz brings nearly four decades of healthcare experience, has helped oversee drugs through commercialization, and has licensed drugs to well respected big pharmaceutical companies. With our experienced leadership team, and the progress we made throughout the third quarter, we look forward to building on our momentum, and executing on our strategic plan as we head into 2021.&#8221;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:left;"><b>Recent Milestones and Accomplishments:</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Next Generation Anthracycline - Annamycin</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Announced results from an independent laboratory demonstrating the ability of Annamycin to target lung localized tumors, validating previous internal animal studies</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Successfully completed a pre-IND (Investigational New Drug) meeting with the FDA regarding the development plan for Annamycin, including the clinical study design and dosing strategy for the initial phase 1b/2 protocol for soft tissue sarcomas with lung metastases</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Announced positive preclinical data corroborating the efficacy of Annamycin in lung metastases at AACR</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Received approval to accelerate European clinical trial in AML, URPL doubled dose escalation. Currently in process with Polish regulatory authorities to open two additional clinical sites for the Phase 1/2 clinical study</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Announced positive independent report confirming absence of cardiotoxicity in Annamycin (unlike currently approved anthracyclines)</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Successfully completed Phase 1 portion of the AML Phase 1/2 trial in the US with positive results</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Immune/Transcription Modulators - WP1066 Portfolio</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Announced preliminary data from the Phase 1 clinical trial of WP1066, in patients with glioblastoma (GBM). Data supports the progression of trial to the fourth and final dose escalation cohort</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Reported positive interim results in Emory University pediatric brain tumor Phase 1 clinical trial. One patient with diffuse intrinsic pontine glioma (DIPG) showed an apparent response to the treatment with both clinical improvement and radiologic reduction of tumor size</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Reported preclinical data demonstrating that WP1066 used in combination with traditional whole brain radiation therapy (WBRT) resulted in long-term survivors and enhanced median survival time relative to monotherapy in mice with implanted human brain tumors</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Patent protection filed by our licensor covering combination of immune stimulating/transcriptional modulator, including combination with radiation therapy</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Received Orphan Drug Designation from FDA</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Infectious Disease and Metabolism/Glycosylation Inhibitors</b><b>- WP1122, WP1096 and WP1097 Portfolio</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Entered into an agreement with the University of Campinas in S&#227;o Paulo, Brazil to further research the anti-viral capabilities of WP1122, specifically for the coronavirus</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Announced in vitro results demonstrating the significant antiviral activity of WP1096 and WP1097, in a range of infectious diseases including against: SARS-CoV-2, HIV, Zika and Dengue Fever</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Independent research conducted at the University of Campinas in S&#227;o Paulo, Brazil demonstrated that SARS-CoV-2 infection is supported by elevated glucose levels and that inhibition of glycolysis with 2-DG effectively eliminated viral load in vitro</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Corroborated antiviral activity of WP1122 against coronavirus in pre-clinical testing at IIT Research Institute in another virus host cell line</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Agreement with Sterling Pharma USA LLC for U.S. production of WP1122 to support expanded development efforts</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Two rounds of preclinical assessment of the potential for WP1122 to address COVID-19 at ImQuest BioSciences demonstrated that WP1122 has an antiviral effect on HCoV-229E. The virus yield reduction assay demonstrated a 5 to 10-fold inhibition of coronavirus production by WP1122 when compared to untreated virus control.</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">University of Frankfurt found 2-DG to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100% in in vitro testing</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Patent filed by our licensor covering WP1122 as anti-viral drug candidate</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Corporate Strategy</b><b> and Events</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Appointed Elizabeth (Liz) Cermak, an accomplished life sciences board director with deep pharmaceutical business development expertise, to Board of Directors</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Participated in a panel at ROTH Capital's, "COVID-19 Therapeutics in Development," healthcare event</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Presented virtually at the H.C. Wainwright &amp; Co. 22nd Annual Global Investment Conference, the Oppenheimer Fall Healthcare Life Sciences &amp; MedTech Summit and the LD Micro 500 Virtual Investor Conference in September</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Presented at the Life Sciences Investor Forum in June</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">&#8226;</td>
			<td style="vertical-align:top;">In November replaced our prior purchase agreement with Lincoln Park Capital with a new $22 million purchase agreement, including an initial investment of $2 million, with enhanced capabilities to draw upon</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><b>Anticipated 2020 Milestones</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">IND submission for Annamycin for the treatment of tumor metastases to the lung</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Expanding infectious disease portfolio via preclinical testing of WP1122 in preparation for submitting an IND for a COVID-19 clinical trial in the first half of 2021</p>
			</td>
		</tr>
		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Continued clinical testing in adult and pediatric brain tumors with WP1066 via physician sponsored trials</p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:left;"><b>Financial Results for the Quarter Ended September 30, 2020</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Research and development (R&amp;D) expense was $4.4 million and $2.8 million for the three months ended September 30, 2020 and 2019, respectively. The increase of $1.6 million is mainly related to increased clinical trial activity, increased license fees and costs related to sponsored research agreements, costs related to manufacturing of additional drug product and two additional employees in R&amp;D headcount.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">General and administrative expense was $1.7 million for the three months ended September 30, 2020 and 2019, respectively.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Loss from operations for the third quarter was $6.2 million compared to a net loss of $4.5 million for the third quarter of 2019. This increase was largely due to the above-mentioned increase in R&amp;D.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Net loss for the third quarter of 2020 was $3.4 million, compared to a net loss of $4.1 million in the third quarter of 2019, and was attributed to the above-mentioned increase in R&amp;D and the change in fair value on revaluation of warrant liability associated with warrants issued in conjunction with stock offerings. Changes in our stock price can result in a material gain or loss during the quarter related to the revaluation of our warrant liability. The gain from the change in the fair value of the warrant liability for the third quarter of 2020 was $2.7 million compared to a gain of $0.1 million in the same quarter in 2019. This is a non-cash item.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Liquidity and Capital Resources</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">As of September 30, 2020, we had cash and cash equivalents of $12.8 million and prepaid expenses and other of $2.5 million. We also had $1.3 million of accounts payable and $2.1 million of accrued expenses. A significant portion of the accounts payable and accrued expenses are due to work performed in relation to our clinical trials. For the nine months ended September 30, 2020 and 2019, we used approximately $14.6 million and $12.5 million of cash in operating activities, respectively, which represents cash outlays for research and development and general and administrative expenses in such periods. For the nine months ended September 30, 2020 and 2019, net proceeds from financing activities were $17.1 million and $20.9 million, respectively, predominately from the sale of our common stock and the exercise of warrants. Cash used in investing activities for the nine months ended September 30, 2020 and 2019 was approximately $0.4 million and $0.04 million, respectively.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We believe that our existing cash and cash equivalents as of September 30, 2020 plus the $2.6 million cash raised and committed subsequent to the quarter will be sufficient to fund our planned operations into the third quarter of 2021, without the issuance of additional equity for cash. Any such issuances should extend the funding of our planned operations beyond the third quarter of 2021. Such plans are subject to our stock price, market conditions, changes in planned expenses depending on clinical enrollment progress, the use of drug product or a combination thereof.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>About Moleculin Biotech, Inc.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">For more information about the Company, please visit http://www.moleculin.com.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability to make an IND submission for WP1122 in the first half of 2021; establishing a recommended Phase 2 Dose for Annamycin in 2021; the ability to make an IND submission for Annamycin for the treatment of tumor metastases to the lung in 2020; and the ability to file for W1122 an IND application or its equivalent for either cancer-related or virus-related clinical trials in the first half of 2021. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC.&nbsp; Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Contacts</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">James Salierno / Carol Ruth</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Ruth Group</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">973-255-8361 / 917-859-0214</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>jsalierno@theruthgroup.com</u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>cruth@theruthgroup.com</u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>-- </b><b>Financial</b><b> </b><b>Tables Follow</b><b>--</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Moleculin Biotech, Inc.</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Unaudited Condensed Consolidated Balance Sheets</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>(in thousands)</b></p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>September </b></b><b><b>30, 2020</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31, 2019</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Current assets:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,795</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,735</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses and other current assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,455</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,749</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total current assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,250</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,484</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Furniture and equipment, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">522</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">316</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,148</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,148</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating lease right-of-use asset</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">224</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">287</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,144</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,235</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Current liabilities:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accounts payable and accrued expenses and other current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,438</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,570</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,438</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,570</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating lease liability - long-term, net of current portion</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">190</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">276</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrant liability - long term</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,049</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,818</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,677</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,664</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total stockholders' equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,467</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,571</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total liabilities and stockholders' equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,144</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,235</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Unaudited Condensed Consolidated Statements of Operations</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".lead.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.B5" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".trail.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Three Months Ended September 30,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Nine Months Ended September, 30</b></b></p>
			</td>
			<td id=".trail.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>(in thousands, except share and per share amounts)</b></p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2020</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2019</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2020</b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2019</b></b></p>
			</td>
			<td id=".trail.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Revenues</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,435</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,785</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,971</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,816</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative and depreciation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,716</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,723</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,276</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,895</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total operating expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,151</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,508</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,247</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,711</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loss from operations</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6,151</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,508</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p>
			</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(16,247</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p>
			</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(12,711</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other income:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gain from change in fair value of warrant liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,743</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">124</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,489</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,059</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other income, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Interest income, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss before taxes</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,395</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,374</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p>
			</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14,716</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p>
			</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(9,637</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p>
			</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Income tax benefit</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&#8212;</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">229</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&#8212;</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">229</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Net loss</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(3,395</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,145</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(14,716</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(9,408</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss per common share - basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.06</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.09</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p>
			</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.26</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p>
			</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.24</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding - basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">61,474,857</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,464,746</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">56,979,507</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,034,303</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mbrx-20201113.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 11/10/2020 2:26:21 PM-->
<xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:mbrx="http://www.mbrx.com/20201113" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.mbrx.com/20201113">
<xsd:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20201113_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20201113_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20201113_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.mbrx.com/20201113/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="mbrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>mbrx-20201113_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 11/10/2020 2:26:21 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.mbrx.com/20201113/role/statement-document-and-entity-information" xlink:href="mbrx-20201113.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.mbrx.com/20201113/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>mbrx-20201113_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 11/10/2020 2:26:21 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
<link:label xlink:label="dei_EntityExTransitionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Ex Transition Period</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>mbrx-20201113_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 11/10/2020 2:26:21 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.mbrx.com/20201113/role/statement-document-and-entity-information" xlink:href="mbrx-20201113.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.mbrx.com/20201113/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  \ .,# 2(  A$! Q$!_\0
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M/\/Z#\,--D?P;\2KIVL)-K/!X:9?FN8YF[0QH3)&3RR_(,LO/Z\? ?X,Z/\
ML\?!SPWX(T",QZ3X:L8[* M]Z7:/FD;_ &G8L[>[&OI?$:OE&,AA\RP+_>U5
M>27;:\NTD]/.S[(^7\,\/G6"GB,LS!?NJ3M%ON];1[Q:U\KKNS\4_P#@H9_R
MFFU3_L;-!_\ 15C7J7_!?;X:WOP,_;*\"_%K15:"76[:&83+VU#3I492?<Q-
M /\ MF:Y+]OCX,>,M=_X+"ZGJ]CX0\57NDMXIT.47UOI%Q+;%%CLPS"14*X&
MTY.>,'TK[T_X+>_LXW?[0'[#^H7&D:=<:EK_ (-OX-9LH+6!IKB9,F&=$506
M/[N5FP!SY8KZF6;TL+B\G<I+EE2Y)>DHP6OSLWZ'RD<FJXO!YTHQ?/&LZD-.
ML92>G?2Z5NY\(?MS_$>+_@J!_P %,OAQX1T"?[1X>FM-+TY&A;>L23HM[?/Q
M_$D;E&]X,=JV?^#CG3X-(_:)^'=K;1)!;6WA%HHHT&%C1;F0*H'H !70_P#!
M ']D#7],_:,\2^/?%/AO6M$B\+:6++31J5A+:&6YNB0[H)%!;;%&ZG'3SA4G
M_!PW\*/%7Q!_:-\$7&@>&/$>NV\'AAXY)=.TR>Z2-_M4AVEHU(!QS@\UT87%
M8;#\2X3*L/)>RP].2O?[4E=OMJK?.YSXG"8K$\+XO-L3!^UQ-6+M9_#%V2MO
MIK\K'S[_ ,%:_'VHZWXB^#FBS22#3O#GPLT-[2(D[!)/!OED ]3LC4_]<Q7[
M/?LQ?!;PSX6_8]\&^#8-)L)?#TOANVM[FT:$-%>B6!3,T@Z,9&9F8GJ6-?!/
M_!1K_@FEXK_:(_96^#OC[P7I%SJ'BSPOX)TW2-9T/R]EY=VRVZ.IC1L$RQ.T
M@,9^9@^!RNT\'\+/^"V_Q5^"/[/MA\-KSX67EWXWT&P71]/U2Z2XB=%C3RXF
MFLS#N>1%"@X<!BN3C)KR,TP=7/,GPU#*9)RI2ESQYDFG?XM6O-W\].I[&48V
MED.<XK$9Q%J-:$>27*Y)JR]U63UV5GIIKT/&O^"7NKW'P9_X*N^'='TB64V,
MVMZGX<F0,<7%IMG4!O4 QQO]4!K'_P""5?BJX\"?ML3:Y9\W>C>'/$5] ",Y
M>+3[AU_517U3_P $5?\ @FQXV\/_ !A/QG^(VDW^@KI\$YT*RU&(QWM]<SHR
MO=21D;D0([A0P#,TF[ "@MXK_P $A/V>_%5I_P %!-(_X23P9XJT_0[S3]8M
M;F>^TBXMX-DMI*FTNZ!1NW8'/.:^JQ^:X*K_ &BH34N2C",G=:M>U;2[Z/\
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' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>mbrx20201110_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mbrx-20201113.xsd" xlink:type="simple"/>
    <context id="d20208K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2020-11-13</startDate>
            <endDate>2020-11-13</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20208K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20208K">0001659617</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20208K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20208K">2020-11-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20208K">MOLECULIN BIOTECH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20208K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20208K">001-37758</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20208K">47-4671997</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20208K">5300 Memorial Drive, Suite 950</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20208K">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20208K">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20208K">77007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20208K">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20208K">300-5160</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20208K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20208K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20208K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20208K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="d20208K">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="d20208K">true</dei:EntityExTransitionPeriod>
    <dei:Security12bTitle contextRef="d20208K">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20208K">MBRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20208K">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140546007067976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 13, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">MOLECULIN BIOTECH, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Nov. 13,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-37758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">47-4671997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">5300 Memorial Drive, Suite 950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">77007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">300-5160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity, Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001659617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *@[;5$'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "H.VU1"4 [FNX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R$Z@8R;UI:.G#@8K;.QF;+4UBQ-C:R1]^SE9FS*V!]C1TN]/
MGT"-"=+T$9]C'S"2PW0W^K9+TH0U.Q$%"9#,";U.94YTN7GHH]>4G_$(09L/
M?42H.%^!1])6DX8)6(2%R%1CC301-?7Q@K=FP8?/V,XP:P!;]-A1 E$*8&J:
M&,YCV\ -,,$(HT_?!;0+<:[^B9T[P"[),;DE-0Q#.=1S+N\@X.UI]S*O6[@N
MD>X,YE_)23H'7+/KY-=Z\[C?,E7QBA="%*+>\WM9/4BQ>I]<?_C=A'UOW<']
M8^.KH&K@UUVH+U!+ P04    " "H.VU1F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M *@[;5&I6(F%4 0  .\0   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME9C;<NHV%(:O=Y]"PU4[$^(#!\,>8(80TC [(32PNSOM]$+8 C2Q)2K)(;Q]
MEPS8=&J6R0T^ZM<G::U_R?1V4KWI#6.&?"2QT/W:QICM5\?1X88E5-_*+1/P
M9"550@U<JK6CMXK1*&N4Q([ONFTGH5S4!KWLWDP->C(U,1=LIHA.DX2J_1V+
MY:Y?\VJG&Z]\O3'VAC/H;>F:S9GYOITIN')RE8@G3&@N!5%LU:\-O:]W?LLV
MR-[XG;.=/CLG=BA+*=_LQ23JUUQ+Q&(6&BM!X?#.1BR.K1)P_',4K>5]VH;G
MYR?UAVSP,)@EU6PDXQ\\,IM^K5,C$5O1-#:O<O?(C@/* $,9Z^R7[ [O-ELU
M$J;:R.38& @2+@Y'^G&<B+,&#>]" __8P,^X#QUEE/?4T$%/R1U1]FU0LR?9
M4+/6 ,>%796Y4?"40SLSN)=A"I-LR%!$9"P,-WLR$8?5AEGK.08ZL:\ZX5'P
M[B#H7Q"<RO=;XC5NB._Z[G^;.\"6 _HYH)_I-:H SZC(7T_P%ID8ENB_D3X:
M>1^-K(_FA3X.X[XAKVS-M5$4>IO2A)4-'A=Z?GD:C[X_3:;D;O*R&(\>;\AD
M.KI%$)LY8A-5/DW##5GLMZ5D>/M._1M"T<HI6E=2S)CBTD9,1"#N2H%PJ5.<
M_/3E2T6DM'.X]E6K.!&A5%NILE"Y(7,#?$0J,I*I,&H/QZB4%U>_'R.(08X8
M7(7XP&-&IFFR9*J,!!=Q7:_>"()6!P'JY$"=JX 6](-,(EA9ON+A(<<NX^&2
MS:#>; =>MQL@?-V<KWL5WS"*%-,Z/R&9 ;R(TH7$)5L-UR7/+)&*TYC<*R@*
M$"0IAR#IMK X]-S"4]W/48^LK4((+N2NW%)QO4=I"X' V,[\WOL<6YX?,R7?
MN0A+I[1"=/$'QE98O>=_CFTFM8%%^I-O+V9MA600N"X6B%Y1(SS<V[,U',+.
MYS(*+A!X#0RDJ 0>;N5/,H0YF6VDP#RD0@22H-[RVFB\%U7!P[W\A^+&, $3
MDR2I.!J(+J7"A58TU@Q#*FJ!A]OU7,8\Y(:+-7F&^+:Y7LJ#JU3R%,;OX:8]
M4ZP>PO0P2+!L.[-@(F**O*Q6%]8/UZLD*RJ A_OU_\@F6J= 5@F(RU8"%B7
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M?9R=;A@%M[(OP/.5E.9T83^2\_\X!O\"4$L#!!0    ( *@[;5&#J:4#U $
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M2P$"% ,4    " "H.VU1"4 [FNX    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "H.VU1F5R<(Q &  "<)P
M$P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( *@[;5&I6(F%4 0  .\0   8              " @0T(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "H.VU1@ZFE ]0!   R!@
M#0              @ &3#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *@[
M;5&7BKL<P    !,"   +              "  9(.  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( *@[;5$ZJJ+G0 $  #P"   /              "  7L/  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "H.VU1)!Z;HJT   #X 0  &@
M            @ 'H$   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " "H.VU199!YDAD!  #/ P  $P              @ '-$0  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   7$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mbrx20201110_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mbrx.com/20201113/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mbrx20201110_8k.htm">mbrx20201110_8k.htm</File>
    <File>ex_213101.htm</File>
    <File>mbrx-20201113.xsd</File>
    <File>mbrx-20201113_def.xml</File>
    <File>mbrx-20201113_lab.xml</File>
    <File>mbrx-20201113_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>logo.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mbrx20201110_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "mbrx-20201113_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mbrx20201110_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mbrx-20201113_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mbrx-20201113_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mbrx-20201113.xsd"
     ],
     "remote": [
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 27,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mbrx",
   "nsuri": "http://www.mbrx.com/20201113",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbrx20201110_8k.htm",
      "contextRef": "d20208K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.mbrx.com/20201113/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbrx20201110_8k.htm",
      "contextRef": "d20208K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document, Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document, Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity, Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity, Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity, Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity, Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity, Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity, Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity, Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity, Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity, Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity, Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20201113/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001437749-20-023720-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-20-023720-xbrl.zip
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MA+$!@Z+854'(X%EV(X,X1%!%JL='\)&G8L\&K)& Y_T4\P.#^0F&_6TP3,S
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M!X'GJ5L\'QML 2)$?2+D<4#E";9&,\)<^WJN,3( 5ISL0*^B)_O].$02A(V
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M(OJJ^1C"K)PC+R.NYX+PD7T!N8=^&J'5C&.;[@=D.$0 AJ^7$NCS'""8.QN
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M^54#96JR4#@*A291RBY=QF*0-=[CZA#L#',G@\OAB=U"*#E=?1N]-N^JG2"
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M[L*J&R#TIF\7M6X_U(V] M&']>A*SS9F2+HC *[$KC;QM7 E!WF#+8&T#D=
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M*FQ;#K9-<:U6Z%:AVW.AVY'5&2O>5UYLJT*)[QFPX(N V<IU%=@60QX(5@/
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MY >EB^L9'E:< "+>4>5HL:6I@4-M]U#HSF7=W'&9R>JK8^5GF'>O;@X*FF]
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M',*$5Y)@QS\^G5O4'_4/XWCE7U!+ P04    " "H.VU1?D=HBSP/   ]:
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M%_"_68E8YEB6R9@Z#JA(B9C<(V;.XEZ9 !\"7Y0(#:5?!BHY_&L,U^'!V*4
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M"Y9LE@HMA6,(?VP:,,#-82Z] 3M^FL<!ZS0=2967SJ8,._B!&;;,CW/N,A@
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M1$[\GRY4_@]02P$"% ,4    " "H.VU1$E=*U>,I  "JX0$ #0
M    @ $     97A?,C$S,3 Q+FAT;5!+ 0(4 Q0    ( *@[;5&_H0GO21D
M &4:   (              "  0XJ  !L;V=O+FIP9U!+ 0(4 Q0    ( *@[
M;5'4;7^2@ ,  ),.   1              "  7U#  !M8G)X+3(P,C Q,3$S
M+GAS9%!+ 0(4 Q0    ( *@[;5%78!;8]@0   PO   5              "
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64$L%!@     '  < N@$  -UF      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
